FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression
Sponsor: Novartis Pharmaceuticals
A PHASE1/PHASE2 clinical study on Hepatocellular Carcinoma (HCC) and Solid Malignancies, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 23 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
23 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1/PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 18 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Completed PHASE1_PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Dec 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Boston, United States , Chuo Ku, Japan , Essen, Germany , Hanover, Germany , Heidelberg, Germany , Hong Kong, Hong Kong , Houston, United States , Lille, France , Los Angeles, United States and 14 more locations